In fact, tumor hypoxia is clinically known to promote resistance to both chemo- and radio-therapy, and HIF-1α is recognized as a molecular target to enhance the cytotoxic effects of chemo- or radio-therapy on cancer cells thereby improving prognosis [1–4]. This evidence concerns the gene HIF1A and neoplasm.